206 related articles for article (PubMed ID: 29783510)
1. Implementation of pharmacogenomics into the clinical practice of therapeutics: issues for the clinician and the laboratorian.
Wu AH; Babic N; Yeo KJ
Per Med; 2009 May; 6(3):315-327. PubMed ID: 29783510
[TBL] [Abstract][Full Text] [Related]
2. The challenges of implementing pharmacogenomic testing in the clinic.
Moyer AM; Caraballo PJ
Expert Rev Pharmacoecon Outcomes Res; 2017 Dec; 17(6):567-577. PubMed ID: 28949250
[TBL] [Abstract][Full Text] [Related]
3. Pharmacogenomics Implementation: Considerations for Selecting a Reference Laboratory.
Vo TT; Bell GC; Owusu Obeng A; Hicks JK; Dunnenberger HM
Pharmacotherapy; 2017 Sep; 37(9):1014-1022. PubMed ID: 28699700
[TBL] [Abstract][Full Text] [Related]
4. Prioritizing pharmacogenomics implementation initiates: a survey of healthcare professionals.
Ho TT; Gift M; Alexander E
Per Med; 2022 Jan; 19(1):15-23. PubMed ID: 34881640
[TBL] [Abstract][Full Text] [Related]
5. Pharmacogenomics and Personalized Medicine.
Cecchin E; Stocco G
Genes (Basel); 2020 Jun; 11(6):. PubMed ID: 32580376
[TBL] [Abstract][Full Text] [Related]
6. Pharmacogenomic testing: perception of clinical utility, enablers and barriers to adoption in Australian hospitals.
Pearce A; Terrill B; Alffenaar JW; Patanwala AE; Kummerfeld S; Day R; Young MA; Stocker SL
Intern Med J; 2022 Jul; 52(7):1135-1143. PubMed ID: 35191159
[TBL] [Abstract][Full Text] [Related]
7. Pharmacogenomics in Pain Management: A Review of Relevant Gene-Drug Associations and Clinical Considerations.
Brandl E; Halford Z; Clark MD; Herndon C
Ann Pharmacother; 2021 Dec; 55(12):1486-1501. PubMed ID: 33771051
[TBL] [Abstract][Full Text] [Related]
8. Assessment of provider-perceived barriers to clinical use of pharmacogenomics during participation in an institutional implementation study.
Borden BA; Galecki P; Wellmann R; Danahey K; Lee SM; Patrick-Miller L; Sorrentino MJ; Nanda R; Koyner JL; Polonsky TS; Stadler WM; Mulcahy C; Kavitt RT; Ratain MJ; Meltzer DO; O'Donnell PH
Pharmacogenet Genomics; 2019 Feb; 29(2):31-38. PubMed ID: 30531377
[TBL] [Abstract][Full Text] [Related]
9. Precision medicine from a citizen perspective: a survey of public attitudes towards pharmacogenomics in Flanders.
Edris A; Callier E; Lahousse L
BMC Med Genomics; 2022 Sep; 15(Suppl 3):193. PubMed ID: 36096833
[TBL] [Abstract][Full Text] [Related]
10. Stakeholder views on pharmacogenomic testing.
Patel HN; Ursan ID; Zueger PM; Cavallari LH; Pickard AS
Pharmacotherapy; 2014 Feb; 34(2):151-65. PubMed ID: 24167008
[TBL] [Abstract][Full Text] [Related]
11. Pharmacoeconomic evaluation of warfarin pharmacogenomics.
You JH
Expert Opin Pharmacother; 2011 Feb; 12(3):435-41. PubMed ID: 21231897
[TBL] [Abstract][Full Text] [Related]
12. Will personalized drugs for cardiovascular disease become an option? - Defining 'Evidence-based personalized medicine' for its implementation and future use.
de Denus S; Dubé MP; Tardif JC
Expert Opin Pharmacother; 2015; 16(17):2549-52. PubMed ID: 26371722
[TBL] [Abstract][Full Text] [Related]
13. Toward Personalized Medicine Implementation: Survey of Military Medicine Providers in the Area of Pharmacogenomics.
DeLuca J; Selig D; Poon L; Livezey J; Oliver T; Barrett J; Turner C; Hellwig L
Mil Med; 2020 Mar; 185(3-4):336-340. PubMed ID: 31786583
[TBL] [Abstract][Full Text] [Related]
14. Pharmacogenomics and warfarin therapy.
Ndegwa S
Issues Emerg Health Technol; 2007 Oct; (104):1-8. PubMed ID: 17912794
[TBL] [Abstract][Full Text] [Related]
15. Assessing the cost-effectiveness of pharmacogenomics.
Veenstra DL; Higashi MK; Phillips KA
AAPS PharmSci; 2000; 2(3):E29. PubMed ID: 11741245
[TBL] [Abstract][Full Text] [Related]
16. Methodological and statistical issues in pharmacogenomics.
Peters BJ; Rodin AS; de Boer A; Maitland-van der Zee AH
J Pharm Pharmacol; 2010 Feb; 62(2):161-6. PubMed ID: 20487194
[TBL] [Abstract][Full Text] [Related]
17. The role of cost-effectiveness analysis in the era of pharmacogenomics.
Flowers CR; Veenstra D
Pharmacoeconomics; 2004; 22(8):481-93. PubMed ID: 15217305
[TBL] [Abstract][Full Text] [Related]
18. Pharmacogenomics and adverse drug reactions in diagnostic and clinical practice.
Manolopoulos VG
Clin Chem Lab Med; 2007; 45(7):801-14. PubMed ID: 17617019
[TBL] [Abstract][Full Text] [Related]
19. How to assess pharmacogenomic tests for implementation in the NHS in England.
Sanghvi S; Ferner RE; Scourfield A; Urquhart R; Amin S; Hingorani AD; Sofat R
Br J Clin Pharmacol; 2023 Sep; 89(9):2649-2657. PubMed ID: 37313748
[TBL] [Abstract][Full Text] [Related]
20. Costing Methods as a Means to Measure the Costs of Pharmacogenomics Testing.
Siamoglou S; Karamperis K; Mitropoulou C; Patrinos GP
J Appl Lab Med; 2020 Sep; 5(5):1005-1016. PubMed ID: 32916714
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
